ABSTRACT
Over a half century ago, Sven Seldinger, M.D., first described the concept of percutaneous vascular entry and thereby introduced a new era of percutaneous therapies (1). Today, with considerable evidence supporting the efficacy of a variety of percutaneous therapies of coronary and non-coronary vascular bed pathologies, diagnostic and therapeutic vascular interventional procedures performed via the common femoral artery (CFA) are increasing. Technological advances in the design of guidewires, sheaths, and guiding catheters to address carotid, brachiocephalic and infrainguinal, renal and mesenteric atherosclerosis, as well as the percutaneous deployed grafts for thoracic and infrarenal aortic pathologies are now effectively treated with percutaneous endovascular techniques. The CFA, in the majority of these interventions, is the preferred portal of entry to this revolution in endovascular therapies.
